Molecular Therapy Oncolytics最新文献_第2页

Bacterial cancer therapy using the attenuated fowl-adapted Salmonella enterica serovar Gallinarum 用减毒家禽适应肠炎血清沙门氏菌治疗细菌性癌症

2区医学

Molecular Therapy Oncolytics Pub Date : 2023-11-01 DOI: 10.1016/j.omto.2023.100745

Daejin Lim, Kwangsoo Kim, Taner Duysak, EunA. So, Jae-Ho Jeong, Hyon E. Choy

引用次数: 0

Beyond ENO1, emerging roles and targeting strategies of other enolases in cancers 除了ENO1，其他烯醇化酶在癌症中的新作用和靶向策略

2区医学

Molecular Therapy Oncolytics Pub Date : 2023-11-01 DOI: 10.1016/j.omto.2023.100750

Jiaojiao Ni, Yihui Huang, Chaoqun Li, Qian Yin, Jieer Ying

引用次数: 0

Treatment with the PPARα agonist fenofibrate improves the efficacy of CD8+ T cell therapy for melanoma 使用PPARα激动剂非诺贝特治疗可提高CD8+ T细胞治疗黑色素瘤的疗效

2区医学

Molecular Therapy Oncolytics Pub Date : 2023-11-01 DOI: 10.1016/j.omto.2023.100744

Mohadeseh Hasanpourghadi, Arezki Chekaoui, Sophia Kurian, Raj Kurupati, Robert Amrose, Wynetta Giles-Davis, Amara Saha, Xu Xiaowei, Hildegund C.J. Ertl

引用次数: 0

Improved oncolytic activity of a reovirus mutant that displays enhanced virus spread due to reduced cell attachment 呼肠孤病毒突变体的溶瘤活性提高，由于细胞附着减少，病毒传播增强

2区医学

Molecular Therapy Oncolytics Pub Date : 2023-11-01 DOI: 10.1016/j.omto.2023.100743

Francisca Cristi, Maiah Walters, Nashae Narayan, Kate Agopsowicz, Mary M. Hitt, Maya Shmulevitz

引用次数: 0

Dual blockade of CD47 and CD24 signaling using a novel bispecific antibody fusion protein enhances macrophage immunotherapy 使用一种新的双特异性抗体融合蛋白双重阻断CD47和CD24信号传导增强巨噬细胞免疫治疗

2区医学

Molecular Therapy Oncolytics Pub Date : 2023-11-01 DOI: 10.1016/j.omto.2023.100747

Yun Yang, He Wu, Yan Yang, Yan Kang, Runjia He, Bei Zhou, Huaizu Guo, Jing Zhang, Jianqin Li, Chunpo Ge, Tianyun Wang

引用次数: 0

Peritoneal-directed chimeric oncolytic virus CF17 prevents malignant ascites and improves survival in gastric cancer peritoneal metastases. 腹膜定向嵌合溶瘤病毒CF17预防恶性腹水并提高癌症腹膜转移的存活率。

IF 5.7 2区医学

Molecular Therapy Oncolytics Pub Date : 2023-10-19 eCollection Date: 2023-12-19 DOI: 10.1016/j.omto.2023.100734

Annie Yang, Zhifang Zhang, Shyambabu Chaurasiya, Anthony K Park, Jianming Lu, Sang-In Kim, Hannah Valencia, Yuman Fong, Yanghee Woo

{"title":"Peritoneal-directed chimeric oncolytic virus CF17 prevents malignant ascites and improves survival in gastric cancer peritoneal metastases.","authors":"Annie Yang, Zhifang Zhang, Shyambabu Chaurasiya, Anthony K Park, Jianming Lu, Sang-In Kim, Hannah Valencia, Yuman Fong, Yanghee Woo","doi":"10.1016/j.omto.2023.100734","DOIUrl":"10.1016/j.omto.2023.100734","url":null,"abstract":"Gastric cancer (GC) peritoneal metastasis (PM) is fatal without effective therapy. We investigated CF17, a new replication-competent chimeric poxvirus, against GC cell lines in vitro and PM in an aggressive GCPM mouse model. We performed viral proliferation and cytotoxicity assays on intestinal-type and diffuse-type human GC cell lines following CF17 treatment. At lower MOIs of 0.01, 0.1, there was >80% killing in most cell lines, while in the more aggressive cell lines, killing was seen at higher MOIs of 1.0 and 10.0. We observed reduced peritoneal tumor burden and prolonged survival with intraperitoneal (i.p.) CF17 treatment in nude mice implanted with the resistant GC cell line. At day 91 after treatment, seven of eight mice were alive in the CF17-treated group vs. one of eight mice in the control group. CF17 treatment inhibited ascites formation (0% vs. 62.5% with PBS). Thus, CF17 efficiently infected, replicated in, and killed GC cells in a dose- and time-dependent manner in vitro. In vivo, i.p. CF17 treatment exhibited robust antitumor activity against an aggressive GCPM model to decrease tumor burden, improve survival, and prevent ascites formation. These preclinical results inform the design of future clinical trials of CF17 for peritoneal-directed therapy in GCPM patients.","PeriodicalId":18869,"journal":{"name":"Molecular Therapy Oncolytics","volume":"31 ","pages":"100734"},"PeriodicalIF":5.7,"publicationDate":"2023-10-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10616379/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71425082","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Neoadjuvant systemic oncolytic vesicular stomatitis virus is safe and may enhance long-term survivorship in dogs with naturally occurring osteosarcoma. 新辅助全身性溶瘤性水疱性口炎病毒是安全的，可以提高自然发生的骨肉瘤犬的长期生存率。

IF 5.7 2区医学

Molecular Therapy Oncolytics Pub Date : 2023-10-14 eCollection Date: 2023-12-19 DOI: 10.1016/j.omto.2023.100736

Kelly M Makielski, Aaron L Sarver, Michael S Henson, Kathleen M Stuebner, Antonella Borgatti, Lukkana Suksanpaisan, Caitlin Preusser, Alexandru-Flaviu Tabaran, Ingrid Cornax, M Gerard O'Sullivan, Andrea Chehadeh, Donna Groschen, Kelly Bergsrud, Sara Pracht, Amber Winter, Lauren J Mills, Marc D Schwabenlander, Melissa Wolfe, Michael A Farrar, Gary R Cutter, Joseph S Koopmeiners, Stephen J Russell, Jaime F Modiano, Shruthi Naik

{"title":"Neoadjuvant systemic oncolytic vesicular stomatitis virus is safe and may enhance long-term survivorship in dogs with naturally occurring osteosarcoma.","authors":"Kelly M Makielski, Aaron L Sarver, Michael S Henson, Kathleen M Stuebner, Antonella Borgatti, Lukkana Suksanpaisan, Caitlin Preusser, Alexandru-Flaviu Tabaran, Ingrid Cornax, M Gerard O'Sullivan, Andrea Chehadeh, Donna Groschen, Kelly Bergsrud, Sara Pracht, Amber Winter, Lauren J Mills, Marc D Schwabenlander, Melissa Wolfe, Michael A Farrar, Gary R Cutter, Joseph S Koopmeiners, Stephen J Russell, Jaime F Modiano, Shruthi Naik","doi":"10.1016/j.omto.2023.100736","DOIUrl":"10.1016/j.omto.2023.100736","url":null,"abstract":"Osteosarcoma is a devastating bone cancer that disproportionally afflicts children, adolescents, and young adults. Standard therapy includes surgical tumor resection combined with multiagent chemotherapy, but many patients still suffer from metastatic disease progression. Neoadjuvant systemic oncolytic virus (OV) therapy has the potential to improve clinical outcomes by targeting primary and metastatic tumor sites and inducing durable antitumor immune responses. Here we describe the first evaluation of neoadjuvant systemic therapy with a clinical-stage recombinant oncolytic vesicular stomatitis virus (VSV), VSV-IFNβ-NIS, in naturally occurring cancer, specifically appendicular osteosarcoma in companion dogs. Canine osteosarcoma has a similar natural disease history as its human counterpart. VSV-IFNβ-NIS was administered prior to standard of care surgical resection, permitting microscopic and genomic analysis of tumors. Treatment was well-tolerated and a \"tail\" of long-term survivors (∼35%) was apparent in the VSV-treated group, a greater proportion than observed in two contemporary control cohorts. An increase in tumor inflammation was observed in VSV-treated tumors and RNA-seq analysis showed that all the long-term responders had increased expression of a T cell anchored immune gene cluster. We conclude that neoadjuvant VSV-IFNβ-NIS is safe and may increase long-term survivorship in dogs with naturally occurring osteosarcoma, particularly those that exhibit pre-existing antitumor immunity.","PeriodicalId":18869,"journal":{"name":"Molecular Therapy Oncolytics","volume":"31 ","pages":"100736"},"PeriodicalIF":5.7,"publicationDate":"2023-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10641240/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"107591785","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Neoadjuvant use of oncolytic herpes virus G47Δ prevents local recurrence after insufficient resection in tongue cancer models. 新辅助使用溶瘤性疱疹病毒G47Δ可预防舌癌模型切除不足后局部复发。

IF 5.7 2区医学

Molecular Therapy Oncolytics Pub Date : 2023-09-21 DOI: 10.1016/j.omto.2023.07.002

Kosuke Inoue, Hirotaka Ito, Miwako Iwai, Minoru Tanaka, Yoshiyuki Mori, Tomoki Todo

{"title":"Neoadjuvant use of oncolytic herpes virus G47Δ prevents local recurrence after insufficient resection in tongue cancer models.","authors":"Kosuke Inoue, Hirotaka Ito, Miwako Iwai, Minoru Tanaka, Yoshiyuki Mori, Tomoki Todo","doi":"10.1016/j.omto.2023.07.002","DOIUrl":"https://doi.org/10.1016/j.omto.2023.07.002","url":null,"abstract":"A complete resection of tongue cancer is often difficult. We investigate the usefulness of administering G47Δ (teserpaturev), a triple-mutated oncolytic herpes simplex virus type 1, prior to resection. G47Δ exhibits good cytopathic effects and replication capabilities in all head and neck cancer cell lines tested. In an orthotopic SCCVII tongue cancer model of C3H/He mice, an intratumoral inoculation with G47Δ significantly prolongs the survival. Further, mice with orthotopic tongue cancer received neoadjuvant G47Δ (or mock) therapy with or without \"hemilateral\" resection, the maximum extent avoiding surgical deaths. Neoadjuvant G47Δ and resection led to 10/10 survival (120 days), whereas the survivals for G47Δ alone and resection alone were 6/10 and 5/10, respectively: all control animals died by day 11. Furthermore, 100% survival was achieved with neoadjuvant G47Δ therapy even when the resection area was narrowed to \"partial,\" providing insufficient resection margins, whereas hemilateral resection alone caused death by local recurrence in half of the animals. G47Δ therapy caused increased number of tumor-infiltrating CD8+ and CD4+ cells, increased F4/80+ cells within the residual tongues, and increased expression of immune-related genes in and around the tumor. These results imply that neoadjuvant use of G47Δ is useful for preventing local recurrence after tongue cancer surgery.","PeriodicalId":18869,"journal":{"name":"Molecular Therapy Oncolytics","volume":"30 ","pages":"72-85"},"PeriodicalIF":5.7,"publicationDate":"2023-09-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/b9/e3/main.PMC10423690.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10366442","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Dynamic fine-tuning of CAR-T cell therapy. CAR-T细胞疗法的动态微调。

IF 5.7 2区医学

Molecular Therapy Oncolytics Pub Date : 2023-09-21 DOI: 10.1016/j.omto.2023.06.001

Pierre V M Trehin, Geisler Muñoz-Guamuro, Wilfried Weber

引用次数: 0

Development of a bicistronic anti-CD19/CD20 CAR construct including abrogation of unexpected nucleic acid sequence deletions. 开发双电子抗cd19 /CD20 CAR结构，包括取消意外的核酸序列缺失。

IF 5.7 2区医学

Molecular Therapy Oncolytics Pub Date : 2023-09-21 DOI: 10.1016/j.omto.2023.07.001

Norris Lam, Richard Finney, Shicheng Yang, Stephanie Choi, Xiaolin Wu, Lauren Cutmore, Jorge Andrade, Lei Huang, Christina Amatya, Margaret Cam, James N Kochenderfer

{"title":"Development of a bicistronic anti-CD19/CD20 CAR construct including abrogation of unexpected nucleic acid sequence deletions.","authors":"Norris Lam, Richard Finney, Shicheng Yang, Stephanie Choi, Xiaolin Wu, Lauren Cutmore, Jorge Andrade, Lei Huang, Christina Amatya, Margaret Cam, James N Kochenderfer","doi":"10.1016/j.omto.2023.07.001","DOIUrl":"https://doi.org/10.1016/j.omto.2023.07.001","url":null,"abstract":"To address CD19 loss from lymphoma after anti-CD19 chimeric antigen receptor (CAR) T cell therapy, we designed a bicistronic construct encoding an anti-CD19 CAR and an anti-CD20 CAR. We detected deletions from the expected bicistronic construct sequence in a minority of transcripts by mRNA sequencing. Loss of bicistronic construct transgene DNA was also detected. Deletions of sequence were present at much higher frequencies in transduced T cell mRNA versus gamma-retroviral vector RNA. We concluded that these deletions were caused by intramolecular template switching of the reverse transcriptase enzyme during reverse transcription of gamma-retroviral vector RNA into transgene DNA of transduced T cells. Intramolecular template switching was driven by repeated regions of highly similar nucleic acid sequence within CAR sequences. We optimized the sequence of the bicistronic CAR construct to reduce repeated regions of highly similar sequences. This optimization nearly eliminated sequence deletions. This work shows that repeated regions of highly similar nucleic acid sequence must be avoided in complex CAR constructs. We further optimized the bicistronic construct by lengthening the linker of the anti-CD20 single-chain variable fragment. This modification increased CD20-specific interleukin-2 release and reduced CD20-specific activation-induced cell death. We selected an optimized anti-CD19/CD20 bicistronic construct for clinical development.","PeriodicalId":18869,"journal":{"name":"Molecular Therapy Oncolytics","volume":"30 ","pages":"132-149"},"PeriodicalIF":5.7,"publicationDate":"2023-09-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/36/9a/main.PMC10465854.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10153670","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0